Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Combination therapy best for head and neck cancer
“Our goal is to cure the cancer as effectively as we can while using as few treatments as possible,” said Ramesh Rengan, assistant professor at University of Pennsylvania
“Our goal is to cure the cancer as effectively as we can while using as few treatments as possible,” said Ramesh Rengan, assistant professor at University of Pennsylvania
The study enrolled healthy male volunteers to compare 48mg of cannabinor delivered intravenously versus placebo on capsaicin induced pain. Capsaicin is the active ingredient in chili peppers. The
The primary study end-point was overall survival and the secondary endpoints were relapse free survival and safety. Both primary and secondary efficacy objectives of the study have been
A total of 184 post-menopausal women out of 217 women randomized to the phase II study, started in October 2006, have completed their 12-week, off-study medication visit. To
The imaging compounds will be developed for diseases such as Alzheimer’s disease, Parkinson’s disease and other disorders also associated with neuroinflammation such as multiple sclerosis. Taisho Pharmaceutical, Nihon
The record profits can also be attributed to the fact that demand for its liquid crystals has increased, said the German drug maker. Merck reported strong performances in
This study was an in-depth look at outcomes from a study published in the New England Journal of Medicine in 2006. That study showed that patients with locally
The proposed acquisition is worth $2 billion and will boost Hospira’s place in generic injectable pharmaceuticals when it gains Mayne Pharma’s pipeline of products. “Following the combination of
The study by Johns Hopkins Kimmel Cancer Center found that the pairing of cholesterol-lowering lovastatin and cyclopamine killed 63% of medulloblastoma cells. By contrast, using either agent alone
Merck originally took the painkiller Vioxx off the market in 2004 after reports that the drug could cause an increase risk of heart attacks. The company believes that